Archives 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 September 29, 2020 Share Subscription into Incanthera plc (“Incanthera”) Read More September 22, 2020 Repayment of Convertible Security – Lind Global Macro Fund, LP Read More September 11, 2020 Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More September 10, 2020 Conversion of Convertible Security – Lind Global Macro Fund, LP Read More September 09, 2020 Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund Read More September 08, 2020 TR1 – Notification of major interest in shares by Lanstead Capital Read More September 08, 2020 Director/PDMR Shareholding/TR-1 Read More September 07, 2020 Placing to raise £6.5 million – update; related party transaction Read More September 03, 2020 Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund Read More September 02, 2020 Placing to raise £6.5 million Read More September 01, 2020 TR1 – Notification of major interest in shares by Lanstead Capital Read More July 27, 2020 Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More 123456…17
September 11, 2020 Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More
September 09, 2020 Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund Read More
September 03, 2020 Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund Read More
July 27, 2020 Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More
